Glucose-dependent insulinotropic polypeptide is a pancreatic polypeptide secretagogue in humans.
Glucose-dependent insulinotropic polypeptide(GIP) has been suggested to stimulate the secretion of pancreatic polypeptide(PP), an islet hormone thought to regulate gut motility, appetite and glycemia. To determine whether human GIP1-42 (hGIP) stimulates PP secretion. As glycemia modulates the secretion of PP, we measured plasma PP concentrations from two studies in healthy men(n=10) and in patients with type 2 diabetes (T2D)(n=12), where hGIP1-42 had been administered intravenously during fasting glycemia, hyperglycemia(12mmol/L) and insulin-induced hypoglycemia (targets: 2.5mmol/L(healthy)/3.5mmol/L(T2D)). Porcine GIP1-42 (pGIP) was also infused intra-arterially in isolated porcine pancreata(n=4). Mean fasting plasma glucose concentrations were ~5mmol/L(healthy) and ~8mmol/L(T2D).At fasting glycemia, PP concentrations were higher during intravenous hGIP1-42 infusion compared with saline in healthy men (mean(SEM), net iAUCs0;30min 403(116) vs. -6(57) pmol/L×min,p=0.004) and in patients with T2D (905(177) vs. -96(86)pmol/L×min,p=0.009). During hyperglycemic clamping, PP concentrations were significantly higher during hGIP1-42 infusion compared with saline in patients with T2D (771(160) vs. -183(117)pmol/L×min,p=0.001), but not in healthy individuals (-8(86) vs. -57(53)pmol/L×min,p=0.69). When PG levels were declining in response to exogenous insulin, PP concentrations were higher during hGIP1-42 infusion compared with saline in healthy individuals (294(88) vs. -82(53)pmol/L×min,p=0.0025), but not significantly higher in patients with T2D(586(314) vs. -120(53),p=0.070). At target hypoglycemia , PP levels surged in both groups during both hGIP1-42 and saline infusions.In isolated pancreata, pGIP1-42 increased PP output in the pancreatic venous effluent (baseline vs. infusion, 24(5) vs. 79(16)pmol/min x min,p=0.044). GIP1-42 increases plasma PP secretion in healthy individuals, patients with T2D and isolated porcine pancreata. Hyperglycemia blunts the stimulatory effect of hGIP1-42 in healthy individuals, but not in patients with T2D.